The role of nimodipine in the treatmet of dementia: The calcium hypothesis of dementia;Stellenwert von nimodipin in der demenztherapie: Calcium-hypothese der demenz

Pharmazie in Unserer Zeit

Volumn 34, Issue 5, 2005, Pages 392-398

  Eckert, Anne ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E4; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CALCIUM ION; CALPAIN; CYCLIN DEPENDENT KINASE 5; DIHYDROERGOTOXINE; DONEPEZIL; G PROTEIN COUPLED RECEPTOR; GALANTAMINE; GINKGO BILOBA EXTRACT; GLUTAMIC ACID; MEMANTINE; NIMODIPINE; NITRIC OXIDE; NOOTROPIC AGENT; PIRACETAM; PRESENILIN 1; PRESENILIN 2; PROTEIN P25; PROTEIN P35; REACTIVE OXYGEN METABOLITE; RIVASTIGMINE; TAU PROTEIN; CALCIUM CHANNEL BLOCKING AGENT;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; ENDOPLASMIC RETICULUM; FAMILIAL DISEASE; GENE MUTATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MENTAL DISEASE; META ANALYSIS; MULTIINFARCT DEMENTIA; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; OXIDATIVE STRESS; PROTEIN PROCESSING; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; ANIMAL; CALCIUM SIGNALING; DRUG EFFECT; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM SIGNALING; DEMENTIA; DEMENTIA, VASCULAR; HUMANS; NIMODIPINE;

EID: 26944438393     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200500138     Document Type: Article

References (12)

1. [1 ] Gertz, H.J., Wolf, H., Arendt, T.: Vascular Dementia. Nervenarzt 73 (2002), 393-404.
2. Mattson, M.P., Rydel, R.E., Lieberburg, I., Smith-Swintosky, V.L.: Altered calcium signaling and neuronal injury: stroke and Alzheimer's disease as examples. Ann. N.Y. Acad. Sci. 679 (1993), 1 -21.
3. Müller, W.E., Eckert, A., Hartmann, H., Velbinger, K., Förstl, H.: The calcium hypothesis of brain aging. Nervenarzt 67 (1996), 15-24.
4. Müller, W.E., Hartmann, H., Eckert, A., Velbinger, K., Förstl, H.: Free intracellular calcium in aging and Alzheimer's disease. Ann. N.Y. Acad. Sci. 786 (1996), 305-320.
5. Peruche, B., Krieglstein, J.: Mechanisms of drug actions against neuronal damage caused by ischemia - an overview. Prog. Neuropsychopharmacol. Biol. Psychiatry 17 (1993), 21-70.
6. Krieglstein, J., Weber, J.: Calcium entry blockers protect brain energy metabolism against ischemic damage. Adv. Exp. Med. Biol. 200 (1986), 243-251.
7. Horn, J., de Haan, R.J., Vermeulen, M., Luiten, P.G.M., Limburg, M.: Nimodipine in animal model experiments of focal cerebral ischemia - A systematic review. Stroke 32 (2001 ), 2433-38.
8. Mohr, J.P., Orgogozo, J.M., Harrison, M.J.G., Hennerici, M., Wahlgren, N.G., Gelmers, H.J., Martinez-Vila, E., Dycka, J., Tettenborn, D.: Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc. Dis. 4 (1994), 197-203.
9. Lopez-Arrieta, Birks, J.; Nimodipine for primary degeneratice, mixed and vascular dementia (review). The Cochrane Database of Systemic Reviews (2002), Issue 3. Art. No.: CD000I47.
10. Pantoni, L., del Ser, T., Soglian, A.G., Amigoni, S.A, Spadari, G., Binelli, D., Inzitari, D.: Efficacy and safety of nimodipine in subcortical vascular dementia - A randomized placebo-controlled trial. Stroke 36 (2005), 619-24.
11. Arzneiverordnung in der Praxis, Band 31, Sonderheft 4: Therapie-empfehlungen der Arzneimittelkommission der Deutschen Ärzteschaft, Demenz, 3. Aufl. 2004.
12. Fritze, J., Waiden, J.; Clinical findings with nimodipine in dementia: test of the calcium hypothesis. J Neural Transm. 46 (1995), 439-453.